| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
We identified genes and splicing variant which were altered in the tumor endothelial cells. We then validated the results by RT-qPCR, and identified gene A as a novel candidate of the tumor endothelium-related gene. The Cancer Genome Atlas (TCGA) datasets revealed that higher expression of gene A is associated with worse overall survival of CRC patients. Knockdown of gene A in human umbilical vein endothelial cell (HUVEC) suppressed cell proliferation and in vitro tube formation. Injection of siRNA against gene A in mice transplanted with human CRC cells suppressed formation of microvessels in the xenografted tumors. Microarray analysis revealed that knockdown of gene A in HUVEC significantly affected gene expression signatures, including cell cycle regulation and interferon signaling. Our results suggest that gene A may play an important role in the angiogenesis in CRC, and that it could be a potential therapeutic target.
|
